

VEGF (h): 293T Lysate: sc-117031

BACKGROUND

The onset of angiogenesis is believed to be an early event in tumorigenesis and may facilitate tumor progression and metastasis. Several growth factors with angiogenic activity have been described. These include fibroblast growth factors (FGFs), platelet derived growth factor (PDGF) and vascular endothelial growth factor (VEGF). VEGF is a dimeric glycoprotein with structural homology to PDGF. Several variants of VEGF have been described that arise by alternative mRNA splicing. It has been speculated that VEGF may function as a tumor angiogenesis factor *in vivo* because the expression pattern of VEGF is consistent with a role in embryonic angiogenesis. VEGF mRNA is formed in some primary tumors, VEGF is produced by tumor cell lines *in vitro* and VEGF mitogenic activity appears to be restricted to endothelial cells. A member of the PDGF receptor family, Flt, has been identified as a high-affinity receptor for VEGF.

REFERENCES

1. Folkman, J., et al. 1989. Induction of angiogenesis during the transition from hyperplasia to neoplasia. *Nature* 339: 58-61.
2. Conn, G., et al. 1990. Purification of a glycoprotein vascular endothelial cell mitogen from a rat glioma-derived cell line. *Proc. Natl. Acad. Sci. USA* 87: 1323-1327.
3. Ferrara, N., et al. 1991. The vascular endothelial growth factor family of polypeptides. *J. Cell. Biochem.* 47: 211-218.
4. Tischer, E., et al. 1991. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. *J. Biol. Chem.* 266: 11947-11954.
5. Plate, K.H., et al. 1992. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas *in vivo*. *Nature* 359: 845-848.
6. Breier, G., et al. 1992. Expression of vascular endothelial growth factor during embryonic angiogenesis and endothelial cell differentiation. *Development* 114: 521-532.
7. Berse, B., et al. 1992. Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages and tumors. *Mol. Biol. Cell* 3: 211-220.
8. De Vries, C., et al. 1992. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. *Science* 255: 989-991.
9. Zhang, L., et al. 1998. Validation of anti-vascular endothelial growth factor (anti-VEGF) antibodies for immunohistochemical localization of VEGF in tissue sections: expression of VEGF in the human endometrium. *J. Pathol.* 185: 402-408.

CHROMOSOMAL LOCATION

Genetic locus: VEGFA (human) mapping to 6p21.1.

PRODUCT

VEGF (h): 293T Lysate represents a lysate of human VEGF transfected 293T cells and is provided as 100 µg protein in 200 µl SDS-PAGE buffer.

APPLICATIONS

VEGF (h): 293T Lysate is suitable as a Western Blotting positive control for human reactive VEGF antibodies. Recommended use: 10-20 µl per lane.


Control 293T Lysate: sc-117752 is available as a Western Blotting negative control lysate derived from non-transfected 293T cells.

VEGF (JH121): sc-57496 is recommended as a positive control antibody for Western Blot analysis of enhanced human VEGF expression in VEGF transfected 293T cells (starting dilution 1:100, dilution range 1:100-1:1,000).

RECOMMENDED SUPPORT REAGENTS

To ensure optimal results, the following support reagents are recommended: 1) Western Blotting: use m-IgGκ BP-HRP: sc-516102 or m-IgGκ BP-HRP (Cruz Marker): sc-516102-CM (dilution range: 1:1000-1:10000), Cruz Marker™ Molecular Weight Standards: sc-2035, UltraCruz® Blocking Reagent: sc-516214 and Western Blotting Luminol Reagent: sc-2048.

DATA



VEGF (JH121): sc-57496. Western blot analysis of VEGF expression in non-transfected: sc-117752 (A) and human VEGF transfected: sc-117031 (B) 293T whole cell lysates.

STORAGE

Store at -20° C. Repeated freezing and thawing should be minimized. Sample vial should be boiled once prior to use. Non-hazardous. No MSDS required.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.